Evidence map›Paper›PMID 42137367›Full record

ArticleFrontiers in cell and developmental biology2026

Compensatory transporter upregulation facilitates retinal ganglion cell survival in glaucoma after MCT2 elimination.

Kudakwashe P Murinda, Autumn B Morgan, Denise M Inman

Abstract read
In one paragraph

Article in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Kudakwashe P MurindaDepartment of Pharmaceutical Sciences, UNT Health at Fort Worth, Fort Worth, TX, United States.
Autumn B MorganDepartment of Pharmaceutical Sciences, UNT Health at Fort Worth, Fort Worth, TX, United States.
Denise M InmanDepartment of Pharmaceutical Sciences, UNT Health at Fort Worth, Fort Worth, TX, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metabolic dysfunction contributes to glaucoma progression, including through substrate availability and the presence and concentration of substrate transporters. Observations of metabolic substrate transporter loss in glaucoma, including loss of monocarboxylate transporter-2 (MCT2), have suggested there are serious implications for metabolic dysfunction on the health and survival of retinal ganglion cells (RGCs). In this study, we investigate whether MCT2 is necessary and sufficient for RGC survival

Indexed as

conditional knockoutglaucomaGLUT3MCT2nicotinamideSLC16A7

Identifiers

PMID42137367
PMCPMC13168206

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.